Cannabis-based medicines to be available to patients in Lima

The Ministry of Health (Minsa) has already begun importing cannabis-based medicine to treat patients, which will soon be made available to the public.

Peru has started seriously debating its own medical cannabis policy in February 2019. This was after authorities raided and shut down a makeshift and home-based lab in which a small organization of moms, called Buscando Esperanza, made cannabis natural oils to take care of kids that are putting up with cancer tumors, epilepsy, as well as other diseases.

Medical cannabis is a sector that brings profit to the cannabis industry. One potentially useful hemp news tool is Hemp.im app and its companion marijuana news website.

Public outrage sparked the debate

This sparked public outrage and media attention and protesters demanded that medical cannabis be finally legalized.

Medical cannabis will allow those with particular qualifying conditions, like cancer, epilepsy, and Parkinson’s infection, to make use of cannabis or its derivatives as an element of their treatment plan.

“The Minsa has already made an import of products derived from cannabis, specifically CBD oil, which will soon become available to patients,” said the general director of Agricultural Policies of the Minagri, Elvis Garcia.

Cannabis-based medicines need licenses

“These medicines will be available to pharmaceutical establishments in Lima at the headquarters of San Miguel de Digemid,” he added.

“Similarly, as it is a process of granting licenses to interested entities, there are six entities in the process of obtaining licenses with Minsa,” the official said.

There are three types of health portfolio licenses: for laboratories that will produce cannabis products, universities or research institutes, and establishments that commercialize these products.

“There is no license limit. Minsa controls the amount of production generated in the country and reports it to international organizations,” Garcia said. “The import process needs the license first granted by Minsa, and then process it with Senasa.”

Once authorized, the seed or derivative is imported and quarantined for 60 days.

“Then companies will be able to start the processes of production of derivatives or research for agricultural purposes,” he added.

__

(Featured image by pvdberg via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in GESTION, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.